Human epidermal growth factor receptor 2 (HER2) is overexpressed in many cancers and chimeric antigen receptor-T (CAR-T) cells targeting HER2 have been shown in clinical trials to be feasible and safe for treating recurrent or refractory central nervous system (CNS) tumors, potentially bringing new therapies for solid tumors [27]. Here, ERBB2 is linked to cancer.